GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+ hematopoietic malignancies; GTB-C3550, a follow-on to its lead candidates TriKE, GTB-3550; GTB-4550, a single-chain tri-specific single chain variable fragments (scFv) recombinant fusion protein conjugate for the treatment of PD-L1+ solid tumor cancers; and GTB-5550, a single-chain tri-specific scFv recombinant fusion protein conjugate for the treatment of B7H3+ solid tumor cancers. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology; and a collaboration agreement with Cytovance Biologics to provide development services for a TriKE therapeutic for the treatment of coronavirus infection. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Beverly Hills, California.
IPO Year:
Exchange: NASDAQ
Website: gtbiopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $11.00 | Buy | ROTH MKM |
Believe Urgent Change is Needed at Research Solutions to Address Underperformance, Poor Operational Execution, and Lack of Accountability Highlight that Since Roy Olivier Became Chief Executive Officer, Research Solutions' Share Price Has Declined More than 20% THOUSAND OAKS, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Peter Derycz, Bristol Investment Fund Ltd. ("Bristol Fund") and certain of Bristol Fund's affiliates (collectively, the "Group"), who collectively beneficially own approximately 20% of Research Solutions, Inc.'s (NASDAQ:RSSS) outstanding shares, today issued an open letter from Mr. Derycz to RSSS shareholders regarding why change is needed at RSSS and the Group's intention t
BEVERLY HILLS, Calif., Nov. 24, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced that Michael Breen, Executive Chairman and Dr. Greg Berk, President of R&D, Chief Medical Officer and Interim Chief Executive Officer will be hosting a Management Update Conference call on Tuesday, November 30th at 4:30PM Eastern Time. To join the live webcast of the call and view the accom
BEVERLY HILLS, Calif., Aug. 13, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE®) protein biologic technology platform, today provided a general business update of events in the second quarter ending June 30, 2021. "I am pleased with the corporate and clinical development milestones that GT Biopharma continues to achieve throughout the first half of 2021," said Anthony J. Catal
BEVERLY HILLS, Calif., Aug. 6, 2021 /PRNewswire/ -- GT Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager (TriKE™) protein biologic technology platform, today announced that the management team will host a conference call to discuss second quarter 2021 financial results and general business updates on August 13, 2021 at 8:30 a.m. EST. To join the call: U.S. callers should dial 1-877-870-4263 and international
GTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating multiple solid tumor types, including prostate, breast, head and neck, ovarian, lung, liver, and GIGTB-7550 TriKE® targets CD19 and is in preclinical development for the treatment of Lupus and other autoimmune indicationsCash of approximately $6.5 million as of September 30, 2024, anticipated to be sufficient to fund operations into Q2 2025 SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIR
SAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced that Dr. Jeffrey Miller, MD1, from the University of Minnesota Medical School2 and GT Biopharma's Consulting Senior Medical Director, will participate in a panel discussion on innovative therapies for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) at the 3rd Annual ROTH Healthcare Opportunities Conference taking place October 9, 2024 in New York, NY. Company management will also
SAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced it will host a virtual KOL event on Thursday, October 10, 2024 at 12:00 PM ET. To register, click here. The event will feature Jeffrey Miller, MD1 and Mark Juckett, MD from the University of Minnesota Medical School2, who will give an overview of the NK cell therapy landscape, discuss current limitations and provide perspective on the future direction of the field as it expands into exciting
GTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in 1H 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating six solid tumor types, including prostate, breast, head and neck, ovarian, lung, and GIGTB-7550 TriKE® is in preclinical development for autoimmune indications and targets CD19Cash of approximately $9.2 million as of June 30, 2024, anticipated to be sufficient to fund operations into 2025 SAN FRANCISCO, CALIFORNIA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive solid tumors expected in Q1 2025GTB-5550 Phase 1 dose escalation basket trial initiation expected in 2025 evaluating GTB-5550 in six solid tumor cancers, including prostate, breast, head and neck, ovarian, lung, and GICash runway anticipated to be sufficient to fund operations into 2025 SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK
BRISBANE, CALIFORNIA, May 21, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ:GTBP) (the "Company"), today announced that it has entered into a definitive securities purchase agreements for the purchase and sale of 740,000 shares of the Company's common stock at a purchase price of $4.35 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue warrants to purchase up to 740,000 shares of common stock. The warrants have an exercise price of $4.35 per share, will be exercisable immediately and will have a term of five years following the date of issuance. The closing of the offering is exp
IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650 expected in 2H 2024Anticipate IND submission for GTB-5550 TriKE® for treatment of B7H3 positive solid tumors in Q4 2024Plan to initiate a Phase 1 dose escalation basket trial evaluating GTB-5550 in six solid tumor cancers – prostate, breast, head and neck, ovarian, lung, and GICash of approximately $9.81 million as of March 31, 2024, provides sufficient runway to fund operations into 2025 BRISBANE, CALIFORNIA, May 15, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused
Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial with GTB-3650 anticipated to start in 2H 2024Anticipate submitting an IND for GTB-5550 targeting B7H3 for multiple solid tumors, including prostate and breast, in Q4 2024Cash of approximately $14 million as of December 31, 2023, provides sufficient runway to fund operations into 2025 BRISBANE, CALIFORNIA, March 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell e
BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ:GTBP) (the "Company"), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, announced today that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30. The reverse stock split will become effective at 5:00 p.m. Eastern time, on February 2, 2024. The Company's common stock will continue to be traded on the Nasdaq Capital Market under the symbol "GTBP" and will begin trading on a post-split basis at the market open on February 5, 2024. The CUSI
The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ:GTBP) (the "Company"), announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended GT Biopharma stockholders entitled to vote at the Company's 2023 Special Meeting of Stockholders (the "Special Meeting") to vote "FOR" Proposal items number 1 and 2. If approved, Proposal No. 1. will provide the Company's Board of Directors (the "Board") with the option to implement a reverse
ROTH MKM initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $11.00
HC Wainwright & Co. initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00
B. Riley Securities initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $21.00
ROTH Capital initiated coverage of GT Biopharma with a rating of Buy and set a new price target of $25.00
4 - GT Biopharma, Inc. (0000109657) (Issuer)
3 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
3 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
4 - GT Biopharma, Inc. (0000109657) (Issuer)
S-1 - GT Biopharma, Inc. (0000109657) (Filer)
8-K - GT Biopharma, Inc. (0000109657) (Filer)
8-K - GT Biopharma, Inc. (0000109657) (Filer)
10-Q - GT Biopharma, Inc. (0000109657) (Filer)
8-K - GT Biopharma, Inc. (0000109657) (Filer)
10-Q - GT Biopharma, Inc. (0000109657) (Filer)
424B3 - GT Biopharma, Inc. (0000109657) (Filer)
EFFECT - GT Biopharma, Inc. (0000109657) (Filer)
S-1/A - GT Biopharma, Inc. (0000109657) (Filer)
8-K - GT Biopharma, Inc. (0000109657) (Filer)
BRISBANE, Calif., Feb. 18, 2022 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® protein biologic technology platform, today announced the appointment of Manu Ohri, who joins the Company as its Chief Financial Officer (CFO) effective immediately. Mr. Ohri, an accomplished accounting and finance executive brings to GT Biopharma over 25 years of management, finance and public accounting experience in working with Boar
BEVERLY HILLS, Calif., Nov. 8, 2021 /PRNewswire/ -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary Tri-specific natural killer (NK) cell engager, TriKE® platform, today announced a restructuring of its executive management team. Mr. Anthony Cataldo, Chairman and Chief Executive Officer and Mr. Michael Handelman, Chief Financial Officer will both pursue other interests. The Board has appointed Dr. Gregory Berk as interim CEO, and Dr. Gavin Choy as acting CFO. Michael Breen has assumed the role of Executive Chairman of the Board, Chair of the Audit Committee and will ove
BEVERLY HILLS, Calif., April 26, 2021 /PRNewswire/ -- GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE™ protein biologic technology platform, today announced the appointment of Gregory Berk, M.D., to the position of Chief Medical Officer. Dr. Berk has served as a Director on GT Biopharma's Board since November 2020, and resigns that post in conjunction with his appointment. The Company is also pleased to announce that Jeffrey S. Mi
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)
SC 13G/A - GT Biopharma, Inc. (0000109657) (Subject)